TheraRadar
← Back
Data updated: Mar 29, 2026

EMD SERONO INC

OncologyNeurologyImmunology
Biotech

EMD SERONO INC is a biotechnology company focused on Oncology, Neurology, Immunology. Key products include BAVENCIO.

1982
Since
18
Drugs
-
Trials
8
Approved (2yr)

Key Drugs

BAVENCIO
avelumab
PD-L1 5 indications · 2017
TEPMETKO
tepotinib hydrochloride
Imidazoline 1 receptor 1 indications · 2021
MAVENCLAD
cladribine
CNS
1 indications · 2019

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

BAVENCIO 2025-06-04
Labeling
BAVENCIO 2024-11-26
Labeling
CETROTIDE 2024-11-18
Manufacturing (CMC)
BAVENCIO 2024-10-11
Efficacy
CETROTIDE 2024-06-04
Labeling
GONAL-F RFF REDI-JECT 2024-05-13
Labeling
GONAL-F RFF REDI-JECT 2024-05-13
Labeling
MAVENCLAD 2024-05-10
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 68%
1 drugs Phase 3: 9 Phase 2: 12 Phase 1: 34
Neurology 12%
1 drugs Phase 3: 2 Phase 2: 1 Phase 1: 1
Immunology 12%
0 drugs Phase 3: 2 Phase 2: 4 Phase 1: 1
Metabolic 4%
1 drugs
Gastroenterology 4%
0 drugs Phase 3: 1 Phase 1: 2

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Takeda big-pharma
Immunology, Oncology, Gastroenterology, Neurology, Metabolic
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Neurology
Amgen biotech
Oncology, Immunology, Metabolic, Gastroenterology, Neurology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Neurology
Pfizer big-pharma
Oncology, Immunology, Gastroenterology